Press Releases

NEW YORK and SHANGHAI, Oct. 2, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"),

BATON ROUGE, La., Oct. 2, 2019 /PRNewswire/ -- The state of Louisiana has partnered with Adaptation Health on the

MUNICH, Oct. 2, 2019 /PRNewswire/ -- Nanion is pleased to announce the launch of Dynamite8, a Dynamic Clamp unit for the multichannel automated patch clamp system, the Patchliner. The Dynamite8 is a Patchliner Add-On which simulates ion channel currents in cells in real-time during patch clamp experiments. This approach will allow higher throughpu

ROCKVILLE, Md., Oct. 2, 2019 /PRNewswire/ -- When one is considering tooth removal, innovations in dental implants have made this treatment solution safe, effective and natural looking when done properly.

CANBY, Ore., Oct. 2, 2019 /PRNewswire/ -- HawkSoft's new text messaging platform automatically handles federal compliance requirements for independent insurance agencies. Recipients of text messages sent through HawkSoft Text Messaging automatically receive the ability to grant opt-in consent so that the insurance agency has documented proof to meet key compliance requir

NEW YORK, Oct. 2, 2019 /PRNewswire/ -- The Mesothelioma Compensation Center says, "We are urging a person who now has mesothelioma because of exposure to asbest

LAGUNA HILLS, Calif., Oct. 2, 2019 /PRNewswire/ -- Sonendo®, Inc., developer of the GentleWave® System, announced today it had been named a winner of the

MORRIS, Ill., Oct. 2, 2019 /PRNewswire/ -- "MRSA must immediately become a top political priority- people are dying and suffering needlessly," states Jeanine Thomas, founder of World MRSA Day and

RANCHO CORDOVA, Calif., Oct. 2, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary (the "Company"), announced today it has received the $2 million upfront distribution fee pursu

JERSEY CITY, N.J., Oct. 2, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that data, which further demonstrates the potential of ibrexafungerp as a treatment for invasive fungal infections, will be presented at IDWeek 2019,